Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in the receptor tyrosine kinase pathways (RTK) for driving tumor growth in over 80% of GB...

Full description

Bibliographic Details
Main Authors: Avadhut D Joshi, Watcharin Loilome, I-Mei Siu, Betty Tyler, Gary L Gallia, Gregory J Riggins
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3462750?pdf=render

Internet

http://europepmc.org/articles/PMC3462750?pdf=render

Similar Items